Self-Hypnotic Relaxation Therapy During Invasive Procedures
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine the effectiveness of self-hypnotic relaxation on mental and physical distress during and after tumor treatment procedures.
| Condition | Intervention | Phase |
|---|---|---|
|
Uterine Neoplasms Leiomyoma |
Behavioral: Self-hypnotic relaxation |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Midcareer Development of Nonpharmacologic Analgesia |
| Estimated Enrollment: | 390 |
| Study Start Date: | April 2002 |
| Study Completion Date: | November 2006 |
| Primary Completion Date: | November 2006 (Final data collection date for primary outcome measure) |
Pain relievers and sedatives may have limited effectiveness and serious side effects when given to alleviate distress during minimally invasive surgical procedures. Unabated distress may interfere with the ongoing procedure and may negatively impact future interventions.
Studies have shown that nonpharmacologic analgesia in the form of self-hypnotic relaxation during invasive medical procedures significantly reduces patients' pain, anxiety, drug use, and number of complications. The long-term goal of this study is to determine whether self-hypnotic relaxation therapy can be a safe and practical method for reducing cognitive and physiologic distress associated with invasive procedures.
Participants in this study will be randomly assigned to one of three groups: a standard care group, an empathic control group, and a self-hypnotic relaxation group. The emphatic control group will meet with a clinician who will offer encouragement and support. The group assigned to self-hypnotic relaxation will read a standardized script prior to procedure. Self-report questionnaires will be used to assess pain and anxiety.
Eligibility| Ages Eligible for Study: | 18 Years to 90 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Referred for transcatheter embolization for benign uterine fibroid tumor or radiofrequency ablation or chemoembolization for malignant tumors
- Able to hear and understand English
Exclusion Criteria:
- Impaired mental function
- Psychosis
- Severe chronic obstructive pulmonary disease
- Intolerance of midazolam or fentanyl
- Weigh less than 121 lbs
- Pregnancy
Contacts and Locations| United States, Massachusetts | |
| Beth Israel Deaconess Medical Center | |
| Boston, Massachusetts, United States, 02215 | |
| Principal Investigator: | Elvira Lang, MD | Beth Israel Deaconess Medical Center |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00087841 History of Changes |
| Other Study ID Numbers: | K24 AT001074-01 |
| Study First Received: | July 14, 2004 |
| Last Updated: | January 15, 2008 |
| Health Authority: | United States: Federal Government |
Keywords provided by National Center for Complementary and Alternative Medicine (NCCAM):
|
Hypnosis Analgesia Embolization, Therapeutic Chemoembolization, Therapeutic |
Additional relevant MeSH terms:
|
Neoplasms Leiomyoma Myofibroma Uterine Neoplasms Neoplasms, Muscle Tissue Neoplasms, Connective and Soft Tissue Neoplasms by Histologic Type Neoplasms, Connective Tissue Connective Tissue Diseases Genital Neoplasms, Female |
Urogenital Neoplasms Neoplasms by Site Uterine Diseases Genital Diseases, Female Hypnotics and Sedatives Central Nervous System Depressants Physiological Effects of Drugs Pharmacologic Actions Central Nervous System Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on June 17, 2013